The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke?

Thrombosis Journal

Research

Sophie Simon¹  Lucas Schirmer¹  Holger Poppert¹  Tobias Boeckh-Behrens²  Johannes Kaesmacher²  Claus Zimmer²  Justus Kleine³ 

[1] Department of Neurology, University Hospital Rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675, Munich, Germany;Department of Neuroradiology, University Hospital Rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675, Munich, Germany;Department of Neuroradiology, Vivantes Klinikum Neukölln, Rudowerstr. 48, 12351, Berlin, Germany;

关键词: Stroke;    Mechanical thrombectomy;    Thrombus;    Histology;    CD31;    Inflammation;   

DOI  :  10.1186/s12959-017-0134-4

 received in 2017-01-14, accepted in 2017-04-08,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe transmembrane receptor molecule CD31 is known to have immunomodulatory functions, suggesting a possible neuroprotective effect in the context of acute ischemic stroke by restricting an over-activation of secondary immunological processes. This study examines the density of CD31+ cells in mechanically extracted thrombi of stroke patients with the aim to test whether the occurrence of CD31+ cells was associated with a beneficial clinical outcome in those patients.MethodsThrombi of 122 consecutive patients with large anterior circulation stroke were collected during intracranial mechanical recanalization. Out of these, 86 immunostained specimens of adequate quality could be analysed. The density of CD31+ cells was quantified and compared with clinical outcome data of the affected patients.ResultsThe density of CD31+ cells was positively related to early patient improvement (ΔNIHSS, r = 0.283, p = 0,012) with an even clearer relationship after exclusion of patients who died in the early hospital phase (r = 0.371, p = 0.001). This finding stayed stable also in the multivariate analysis after corrrection for other outcome-influencing factors (p = 0.049).ConclusionThis study shows a stable relation between CD31+ cells and early clinical improvement of patients with acute ischemic stroke. This finding is in line with recent reports showing immunomodulatory and potential neuroprotective effects of CD31, suggesting that CD31 may be a promising neuroprotective agent in stroke patients.

【 授权许可】

CC BY   
© The Author(s). 2017